These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21088574)

  • 41. Focal and segmental glomerulosclerosis and plasma cell proliferative disorders.
    Dingli D; Larson DR; Plevak MF; Grande JP; Kyle RA
    Am J Kidney Dis; 2005 Aug; 46(2):278-82. PubMed ID: 16112046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Collapsing glomerulopathy.
    Schwimmer JA; Markowitz GS; Valeri A; Appel GB
    Semin Nephrol; 2003 Mar; 23(2):209-18. PubMed ID: 12704581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity.
    Wisse BE
    J Am Soc Nephrol; 2004 Nov; 15(11):2792-800. PubMed ID: 15504932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
    Bilan VP; Salah EM; Bastacky S; Jones HB; Mayers RM; Zinker B; Poucher SM; Tofovic SP
    J Endocrinol; 2011 Sep; 210(3):293-308. PubMed ID: 21680617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of chronic kidney disease in Jing adults in China: a village-based study.
    Xue C; Ye XD; Li W; Peng Q; Ding HY; Zhang YH; He DF; Bai X; Huang Y; Song YS; Pang L; Liao YH
    Clin Nephrol; 2013 Jan; 79(1):50-6. PubMed ID: 22948117
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
    Blanco S; Vaquero M; Gómez-Guerrero C; López D; Egido J; Romero R
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):557-65. PubMed ID: 15831368
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Focal segmental glomerulosclerosis is not a sufficient predictor of renal outcome in patients with membranous nephropathy.
    Heeringa SF; Branten AJ; Deegens JK; Steenbergen E; Wetzels JF
    Nephrol Dial Transplant; 2007 Aug; 22(8):2201-7. PubMed ID: 17442739
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The importance of overweight and obesity for the development and progression of renal diseases].
    Klassen A; Bahner U; Sebekova K; Heidland A
    Dtsch Med Wochenschr; 2004 Mar; 129(11):579-82. PubMed ID: 14997412
    [No Abstract]   [Full Text] [Related]  

  • 49. Trends in the epidemiology of focal segmental glomerulosclerosis.
    Kitiyakara C; Kopp JB; Eggers P
    Semin Nephrol; 2003 Mar; 23(2):172-82. PubMed ID: 12704577
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metabolic syndrome and chronic kidney disease.
    Guarnieri G; Zanetti M; Vinci P; Cattin MR; Pirulli A; Barazzoni R
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S19-23. PubMed ID: 20797564
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies.
    O'Donnell MP; Kasiske BL; Cleary MP; Keane WF
    J Lab Clin Med; 1985 Nov; 106(5):605-10. PubMed ID: 4056571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epidemiology of obesity and chronic kidney disease.
    Ross WR; McGill JB
    Adv Chronic Kidney Dis; 2006 Oct; 13(4):325-35. PubMed ID: 17045219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Obesity-Related Glomerulopathy: A Latent Change in Obesity Requiring More Attention.
    Yang S; Cao C; Deng T; Zhou Z
    Kidney Blood Press Res; 2020; 45(4):510-522. PubMed ID: 32498064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Obesity-related glomerulopathy and the nephron complement.
    Tsuboi N; Utsunomiya Y; Hosoya T
    Nephrol Dial Transplant; 2013 Nov; 28 Suppl 4():iv108-13. PubMed ID: 23868145
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overweight, obesity and metabolic alterations in chronic kidney disease.
    Zoccali C
    Prilozi; 2009 Dec; 30(2):17-31. PubMed ID: 20087247
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis.
    D'Agati VD; Chagnac A; de Vries AP; Levi M; Porrini E; Herman-Edelstein M; Praga M
    Nat Rev Nephrol; 2016 Aug; 12(8):453-71. PubMed ID: 27263398
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Obesity-related glomerulopathy: pathogenesis, pathologic, clinical characteristics and treatment.
    Xu T; Sheng Z; Yao L
    Front Med; 2017 Sep; 11(3):340-348. PubMed ID: 28791668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Obesity-related renal injury in childhood.
    Savino A; Pelliccia P; Chiarelli F; Mohn A
    Horm Res Paediatr; 2010; 73(5):303-11. PubMed ID: 20389099
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The biological consequence of obesity on the kidney.
    Kanasaki K; Kitada M; Kanasaki M; Koya D
    Nephrol Dial Transplant; 2013 Nov; 28 Suppl 4():iv1-7. PubMed ID: 23743020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of weight reduction regimens and bariatric surgery on chronic kidney disease in obese patients.
    Abou-Mrad RM; Abu-Alfa AK; Ziyadeh FN
    Am J Physiol Renal Physiol; 2013 Sep; 305(5):F613-7. PubMed ID: 23825072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.